(News Bulletin 247) – AstraZeneca today announced that it has entered into a collaboration, exclusive option and licensing agreement with Quell Therapeutics to develop multiple T-regulatory (Treg) cell therapies that have the potential to be curative in indications for type 1 diabetes (T1D) and inflammatory bowel disease (IBD).
Iain McGill, Managing Director of Quell Therapeutics, said: ‘This collaboration builds on our pioneering work to develop multi-modular Treg cell therapies for immune disorders and is an excellent validation of the technologies and capabilities that we have put in place.’
Mene Pangalos, Executive Vice President of Biopharmaceutical R&D at AstraZeneca, added: This collaboration is part of our strategy to target the underlying factors of the disease in order to stop or slow the progression of the disease and, ultimately, to accelerate the delivery of transformative care to patients with chronic autoimmune diseases.’
AstraZeneca will have the opportunity to further develop and commercialize successful clinical candidates for T1D and IBD. Quell will receive $85 million from AstraZeneca.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
